Charles River Labs stock reaches new 12-month high as 2026 guidance lifts expectations

Charles River Laboratories International Inc. (ISIN US1591881009) stock has climbed to a new 12-month high in mid-August 2026, reflecting investors renewed confidence after the company paired solid second quarter results with upgraded full-year 2026 guidance. As of August 17, 2026, a same-day performance overview showed the shares trading at an intraday high of $288.64 and last quoted around $288.42 on the New York Stock Exchange, up from a prior close of $280.05 and supported by trading volume of 350,686 shares on that session per a recent trading summary.

Fresh highs and market performance

The latest price action places Charles River Labs stock comfortably above many quoted fair-value and target metrics, underlining how strongly the shares have rerated since the company reported its most recent results. One same-day aggregation page noted that the stock traded in a range from roughly $280.01 to $288.42 following the earnings release, with a fair-value indication of $287.38 as of August 17, 2026, at 11:33 a.m. ET, underscoring how current trading levels cluster tightly around independent valuation markers according to the same performance snapshot.

Viewed across a slightly longer horizon, market data compiled in mid-August 2026 show that Charles River Labs stock has delivered a gain of 43.56 percent over the past 12 months, highlighting how the shares have moved from a period of consolidation into a sustained uptrend. A real-time CBOE overview dated August 18, 2026, reported a price of $288.58 at 3:58:55 p.m. ET, with a five-day change of 0.68 percent, a year-to-date gain of 3.51 percent, and a 12-month performance of 43.56 percent, signaling that the latest high builds on a broader recovery rather than a one-day spike based on a CBOE-linked quote overview.

Analyst stance and valuation context

While the share price has pushed to a fresh 12-month high, recent analyst consensus data suggest that the market may now be projecting beyond the average target range. A mid-August 2026 analysis compiled from multiple research reports indicates that Charles River Labs stock carries an average twelve-month price target of $255.65, with individual targets ranging from $175.00 at the low end to $310.00 at the high end, and an overall moderate buy rating drawn from 16 analyst opinions per an analyst consensus overview.

Comparing these figures to current trading levels yields a clear quantified gap: with the stock quoted at $286.44 as of August 17, 2026, at 3:58 p.m. ET, the average target of $255.65 implies downside of 10.8 percent relative to that closing price, even as the highest individual target at $310.00 still sits modestly above the recent 12-month high according to the same consensus summary. The same dataset notes that the shares have advanced 43.5 percent since a reference point tied to prior trading, reinforcing how far the market has moved ahead of the mid-range target band.

Guidance lifts fundamental expectations

A key factor behind the stock s renewed momentum is the company s latest full-year 2026 guidance, which puts specific numbers under its growth ambitions. A news aggregation dated August 5, 2026 highlighted that Charles River Labs updated its outlook to call for 2026 earnings per share in a range from $11.15 to $11.45, signaling double-digit EPS when compared with prior-year baselines and framing management s intention to grow profitability over the next several quarters as summarized in a guidance-focused alert.

In tandem with the EPS range, the same coverage noted that Charles River Labs raised its free cash flow projection for full-year 2026 to a band between $400 million and $420 million, pointing to an incremental cash generation plan that could support debt reduction, disciplined capital expenditure, and select acquisitions or share repurchases according to an overview of the updated guidance. Taken together, the EPS midpoint of $11.30 and free cash flow midpoint of $410 million provide investors with concrete reference points for evaluating both valuation and balance-sheet flexibility.

The guidance also interacts directly with the stock s valuation metrics. Using the August 17, 2026 closing price of $286.44 and the 2026 EPS midpoint of $11.30, the shares trade at a forward price-to-earnings multiple of roughly 25.3 times, while the fair-value indication of $287.38 cited in one intraday snapshot suggests that the market is pricing the stock close to the upper end of recent independent valuations based on the same valuation summary. For investors focused on free cash flow, the $410 million midpoint against a market capitalization inferred from prices in the high $280s implies a free cash flow yield that balances growth expectations with ongoing investment in the business.

Second quarter execution underpins the rally

While the guidance provides a forward-looking anchor, the market s willingness to mark Charles River Labs stock to new highs is also rooted in the company s most recent reported quarter. A second quarter 2026 recap emphasized that revenue growth in that period exceeded internal plans and that margins held up in the face of cost pressures, giving investors confidence that the company can translate its pipeline of preclinical and laboratory services into tangible earnings per a detailed performance review.

The same review pointed out that since reporting these second quarter results, Charles River Labs stock has risen 19.6 percent, demonstrating a clear before-and-after shift in how the market values the company s earnings power. This quantified post-earnings move underscores how investors interpreted the quarterly numbers and updated guidance as a step-change rather than a routine beat, particularly given the combination of resilient revenue, stable margins, and stronger cash flow projections from the same Q2-focused analysis.

In addition, a separate financials overview tied to CBOE pricing indicated a closing price of $286.63 as of August 17, 2026, with a five-day gain of 2.36 percent and a year-to-date change of 4.68 percent, figures that align closely with the intraday quotes cited in other sources and reinforce the picture of a stock grinding higher on the back of fundamental execution per a CBOE-linked financials page.

Insider activity and regulatory filings

Regulatory filings in August 2026 add another layer of context for investors tracking ownership dynamics and potential insider sentiment. A recent compilation of regulatory documents notes that the latest submission for Charles River Labs was a Form 144 filed on August 18, 2026, a disclosure type typically associated with planned sales of restricted or controlled securities by company insiders or large shareholders according to a filings-focused overview.

While the precise volume and pricing terms of the Form 144 are not fully detailed in summary snippets, the presence of such a filing in close proximity to a new 12-month high may signal that some insiders or affiliated holders are taking advantage of elevated valuations to diversify or rebalance their positions. For investors, this combination of strong price performance, upwardly revised guidance, and incremental insider selling disclosures underscores the need to weigh both the company s improved fundamentals and the risk that expectations embedded in the current share price may already be demanding.

Core preclinical services support growth

Behind the numbers, Charles River Labs business model continues to center on providing outsourced preclinical and early-stage development services to pharmaceutical and biotechnology clients. One of the company s flagship offerings sits in its Discovery and Safety Assessment segment, where integrated in vivo efficacy and toxicology studies help clients evaluate candidate therapies before they move into costly clinical trials. The second quarter 2026 performance review highlighted that this segment delivered solid revenue growth and contributed meaningfully to the company s margin profile per the same segment-focused analysis.

By pairing discovery, safety assessment, and related laboratory services, Charles River Labs positions itself as a one-stop partner that can compress timelines and reduce risk for drug developers. In practical terms, this means designing and running studies that measure pharmacokinetics, pharmacodynamics, and toxicology endpoints across multiple species, capturing data that regulators require for investigational new drug applications. The company s guidance for 2026, with EPS in the $11.15 to $11.45 range and free cash flow between $400 million and $420 million, implicitly assumes that demand for these services remains robust and that Charles River Labs continues to capture a meaningful share of outsourced preclinical spend.

Stock perspective and trading venue

For investors tracking the name, Charles River Labs stock trades on the New York Stock Exchange under the ticker CRL, with recent quotes in the high $280s as of the August 17, 2026 session. As of that date, one summary placed the official closing price at $286.44 at 3:58 p.m. ET, with an extended-hours indication of $286.52 at 7:50 a.m. ET and a one-day gain of 2.28 percent, cementing a new 12-month high and marking another incremental leg higher in the stock s post-earnings climb based on a detailed stock quote overview.

Looking ahead, the combination of strong second quarter execution, upgraded full-year 2026 guidance with an EPS midpoint of $11.30 and free cash flow midpoint of $410 million, and a share price that now sits slightly above a $255.65 average target creates a nuanced setup. On one hand, the company is delivering on its plan and enjoys a 43.56 percent 12-month gain; on the other, the implied forward multiple and the divergence between current price and average target remind investors that future quarters will need to sustain or exceed current momentum to keep the valuation supported.

Read more

Investor Relations

Preclinical discovery services as a flagship offering

Among the range of solutions Charles River Labs offers, its preclinical discovery services stand out as a representative example of how the company generates value. These programs typically combine in vitro assays, in vivo disease models, and advanced imaging to help pharmaceutical and biotechnology clients identify lead candidates and optimize dosing strategies before moving into human testing. By integrating study design, execution, and data analysis under a single umbrella, the company aims to shorten development timelines and improve the probability that promising molecules progress successfully through the pipeline according to the company s own solution descriptions.

In the second quarter 2026 performance review, management commentary emphasized that demand for such discovery and safety assessment services remained strong across therapeutic areas, with particular strength in oncology and immunology-related programs per the same segment-level recap. This demand backdrop underpins the company s confidence in its 2026 guidance ranges and supports the notion that the business can sustain both revenue growth and cash generation even as customers navigate evolving funding conditions.

Current stock level and valuation snapshot

As of the close on August 17, 2026, Charles River Labs stock changed hands at $286.44 on the New York Stock Exchange, with extended-hours trading indicating a modest further uptick to $286.52 later that day according to the same quote overview. Combined with the 12-month gain of 43.56 percent reported in CBOE-linked data and the fair-value indication of $287.38 cited in intraday performance summaries, this price situates the stock just shy of $290 while leaving a modest gap to the highest individual analyst target of $310.00.

With full-year 2026 guidance calling for EPS between $11.15 and $11.45 and free cash flow between $400 million and $420 million, investors now must decide whether the current valuation at roughly 25 times the EPS midpoint and an implied free cash flow yield consistent with a high-growth services platform adequately compensates for execution and macro risk. The presence of a Form 144 filing on August 18, 2026, signals that at least some insiders or major holders are locking in gains, yet the broader analyst community s moderate buy consensus and the company s upgraded guidance suggest that many still see room for continued earnings expansion based on the filings summary and consensus data.

Fact box

Company: Charles River Laboratories International Inc.
ISIN: US1591881009
Ticker: CRL
Exchange: New York Stock Exchange (NYSE)
Price (as of August 17, 2026, 3:58 p.m. ET): $286.44 USD
Sector / Industry: Health care / Life sciences tools and services
Index membership: S&P 500